High Prevalence of Short-Chain Acyl-CoA Dehydrogenase Defi ciency in the Netherlands, but No Association with Epilepsy of Unknown Origin in Childhood
Butyryl-CoA (C4-CoA) is the main substrate for the SCAD enzyme and accumulates in mitochondria of patients with decreased SCAD activity, which subsequently leads to increased levels of butyrylcarnitine (C4-C) and ethylmalonic acid (EMA). EMA can best be measured in urine, whereas C4-C can best be measured in plasma and blood spots dried on fi lter paper. These 2 metabolites constitute the major biochemical features of SCADD. The diagnosis of SCADD is usually confi rmed by DNA analyses [23] . The majority of SCADD patients are homozygotes or compound heterozygotes for 2 common SCAD-encoding gene ( ACADS) variants, i. e., c.625G > A and c.511C > T, or for these common ACADS variants in combination with a rare ACADS mutation [20, 22 -24] . Homozygosity for either of the common ACADS variants has been found in the general population with a remarkably high prevalence: approximately 0.3 % for the common c.511C > T and 5.5 % for the common c.625G > A variant [17, 18] ; and this ACADS genotype has been considered to confer susceptibility to the development of clinical Abbreviations ▼ Introduction ▼ Short-chain acyl-CoA dehydrogenase (SCAD) is the fi rst enzyme of the short-chain β -oxidation pathway catalysing dehydrogenation of shortchain fatty acids. SCAD defi ciency (SCADD) is a newly recognised autosomal recessive inborn error of fatty acid oxidation that has been associated with a remarkable variety of clinical symptoms. SCADD is probably one of the more common inborn errors of metabolism [23] . disease [5, 9, 11] . More than 70 diff erent ACADS mutations have been reported so far [5, 10, 11, 14 -16, 19 -21, 23, 24] . The majority of Dutch patients are compound heterozygous for the common c.625G > A variant and one specifi c rare mutation, c.1058C > T [23] located on the c.625G and c.511C ACADS alleles. Overall an ACADS genotype consisting of this specifi c rare mutation and / or common ACADS variants was present in 61 % of Dutch SCADD patients [23] . Most of the reported SCADD patients were initially investigated because of neurological symptoms and / or hypoglycaemia [5, 20, 22 -24] . In our previous study on 31 Dutch SCADD patients [23] , developmental delay was reported in 52 % and epilepsy in 35 % of patients. Behavioural disorders and hypoglycaemia were reported in 26 % and 19 % of this patient group, respectively. No correlation between genotype and phenotype could be established, and in some patients other diagnoses were identifi ed that explained the symptoms initially leading to metabolic studies. Epilepsy is a frequent fi nding in childhood. Studies from Europe and North America report rates from 3.6 to 6.5 / 1000 children [1 -3, 6, 8, 12] . Diagnostic studies fail to establish the cause of epilepsy in up to 30 % of the patients [13] . However, in patients with idiopathic childhood epilepsy, studies for inborn errors of metabolism such as SCADD, as a potential cause are often not performed. Furthermore, the facts that epilepsy is a frequent symptom in SCADD and that the prevalence of SCADD is much higher than the number of patients detected by metabolic studies [23] , suggest that patients with epilepsy related to SCADD may remain undiagnosed.
To test this hypothesis we tested a group of paediatric patients with epilepsy for the presence of SCADD. We aimed to gain knowledge regarding the need for SCADD studies in epilepsy patients. In addition, we aimed to further estimate the extent of SCADD individuals in the Netherlands by establishing the frequencies of the common c.511C > T ACADS variant and the rare c.1058C > T ACADS mutation in the Dutch population.
Patients and Methods ▼ Patients and material
We performed a study involving 131 paediatric patients with epilepsy and 909 anonymous newborns. Blood spots for the reference group were obtained from the RIVM (National Institute for Public Health and the Environment, the Dutch Institute involved in neonatal screening). The sample of newborn screening cards used was proportional to the number of live births in each of 14 screening districts, ensuring adequate demographic representation of the Dutch population. Dutch newborn screening cards are not released for any reason except newborn screening testing during the fi rst 5 years. Consequently, the screening cards used in this study were more than 5 years old. Newborn screening cards were stored at 4 ° C and they were analysed anonymously.
The study was performed in a paediatric patient group with patients aged 16 years or younger at the time of participation. Because all patients in the Dutch SCADD patients group were < 8 years old when epilepsy symptoms started, we restricted the epilepsy group to those with onset of epilepsy at < 8 years. The exclusion criteria included a known or suspected cause of the epilepsy and any previously performed metabolic studies (including SCADD investigations).
Patients with epilepsy were recruited via paediatricians and neurologists within the Academic Medical Center Amsterdam, and 3 Dutch epilepsy centres. Patient and symptom characteristics were obtained using questionnaires answered by parents or legal representatives. Written informed consent was obtained from all patients and / or parents / legal representatives of the patients. The study protocol was approved by the Medical Ethics Committee of the Academic Medical Center in Amsterdam and the RIVM.
DNA PCR-RFLP analysis
DNA was extracted from blood spot samples using Chelex 100 (BioRad) essentially as previously described [7, 25] , but with the following modifi cations. Blood spot samples (6 mm diameter) were washed overnight at 4 ° C with 1 mL sterile water. The next day, the supernatant was discarded, 200 μ L of Chelex (50 g / L, pH 10.6) were added and the sample was incubated at 56 ° C for 30 min. Subsequently, the samples were mixed for 10 s, centrifuged (3 min at 10 000 × g), incubated for 8 min at 96 ° C, mixed again for 10 s and centrifuged (3 min at 10 000 × g). From this mixture, 14.5 μ L of supernatant were used in a 25-μ L PCR reaction.
The extracted DNA was subjected to PCR-RFLP analysis to determine the presence of the common c.625G > A and c.511C > T ACADS variants and the rare c.1058C > T ACADS mutation. Concerning the common c.625G > A variant, a RFLP assay was used as previously described [17] . 
Statistical analyses
SPSS (SPSS 12.0.1), Graphpad Prism 3.0 and CIA (version 1, 1989) software programmes were used to analyse the data from the DNA studies. The sample size necessary for this study was calculated based on previous studies that estimate that 6 % of normal (reference) individuals have ACADS genotypes that are either homozygous or compound heterozygous for the common ACADS variants and / or the rare c.1058C > T mutation [17, 18, 23] . A 3-fold higher frequency, i. e., 18 % in the patient group was supposed to indicate an association between these specifi c ACADS genotypes and epilepsy. Using a 2-tailed test with α = 0.05 and power = 80 % , we estimated that a sample size of at least 65 patients and 260 reference subjects was required.
To estimate the association between the ACADS genotypes and epilepsy, the odds ratio was calculated. 
Results

▼ Incidence of the common c.511C > T and c.625G > A ACADS gene variants and the rare c.1058C > T mutation in the Dutch population reference group
Demographic data of the epilepsy study group
Data from 131 epilepsy patients (66 girls and 85 boys) were studied. Age at study inclusion ranged between 0 and 16 years (median: 9 years). Age of fi rst epileptic insult ranged from 0 to 6 years (median: 3 years). In all patients the epilepsy was defi ned as idiopathic. Normal development was confi rmed in 92 / 131 (70 % ) patients and 39 / 131 (30 % ) patients had delayed cognitive and / or motor function. 
Incidence of the common c.511C > T and c.625G > A ACADS gene variants and the c.1058C > T mutation in the epilepsy study group and comparison with the reference group
In 12 of the 131 patients (9.8 % ), one copy of the common c.511C > T variant was identifi ed, but none of the epilepsy patients were homozygous for this variant ( • ▶ 
Discussion ▼
The current study is the fi rst to investigate the prevalence of the common c.511C > T ACADS variant and the rare c.1058C > T ACADS mutation in the Netherlands. In addition, it is the fi rst study to examine a potential association between SCADD and one of its most frequently associated symptoms: epilepsy. This study included 131 patients and 909 reference subjects, resulting in a power of > 98 % to detect a diff erence of at least 12 % between the reference and the patient groups. Homozygosity and heterozygosity for the common c.511C > T ACADS variant in the Dutch population (0.1 and 8.9 % , respectively) were comparable to the percentages reported for the USA population ( • ▶ Table 1 ) [18] . The prevalence of the most common ACADS variant, c.625G > A, in the Netherlands, has been investigated previously [17] , and the current study provides similar results (5.3 and 35 % , respectively, • ▶ Table 1 ). Because those results are also comparable to numbers reported for the USA population, it appears that both common ACADS variants, which have been considered to confer susceptibility to the development of clinical SCADD, are represented proportionally throughout the Western world. If these common ACADS variants would indeed confer susceptibility for clinical SCADD, this would imply every 1:14 Western newborns to be at risk for " SCADD symptoms " . In the Netherlands, which has an annual birth rate of 180 000 [4] , this corresponds to approximately 12 500 newborns each year. In addition we investigated the prevalence of the rare c.1058C > T mutation, which is thought to represent a Dutch founder mutation [23] . The results of the current study provide evidence for a founder mutation because 0.7 % percent of the reference group was identifi ed with one c.1058C > T copy, all patients carrying the rare c.1058C > T mutation were of Dutch ancestry, and as this rare mutation has not been reported in patients without Dutch ancestors [23] . Based on the established frequencies for this rare Dutch mutation and the common ACADS variants, a birth prevalence as high as 1:1 000 for an ACADS genotype compound heterozygous for an common ACADS variant plus the rare c.1058C > T mutation, can be calculated. This ACADS genotype has been associated with the biochemical features (increased C4-C and / or EMA) of SCADD in all previously reported cases [23] . For the Netherlands this implies that, in addition to approximately 12 500 newborns with supposed susceptibility for clinical SCADD, 180 newborns with SCADD would be born every year. The results of our study demonstrate that the combined prevalence of all SCADD-related genotypes in the Netherlands amounts to at least 1:1 000, which is signifi cantly higher than our previous estimate of 1:3 300 [23] . This is in strong contrast with the fewer than 40 patients with SCADD who have been diagnosed in the Netherlands in recent decades. Failure to diagnose SCADD may be explained if SCADD often presents with clinical signs and symptoms that do not lead to metabolic studies of urine or plasma for increased EMA and / or C4-C concentrations. Because epilepsy appears to be a common clinical symptom in SCADD, and uncomplicated epilepsy in childhood is usually not followed by diagnostic tests for metabolic diseases, a high prevalence of SCADD in patients with unexplained epilepsy may, in part, explain the high number of unrecognised SCADD patients. However, failure to diagnose SCADD may also be explained if SCADD only represents a biochemical condition, not leading to any symptoms. We therefore investigated the presence of the most common ACADS genotypes (representing 61 % percent of ACADS genotypes in the Dutch SCADD patient group) in paediatric patients with epilepsy of unknown origin as well as in reference subjects. However, our study failed to demonstrate an association between SCADD, defi ned as homozygosity or compound heterozygosity for the common c.511C > T and c.625G > A variant and / or the Dutch rare c.1058C > T mutation and epilepsy of unknown origin in childhood.
A fi rst limitation of our study is that we could not exclude an association between idiopathic childhood epilepsy and SCADD with rare mutations on both alleles. In order to do this very high numbers of patients and reference subjects would have been needed, due to the fact that homozygosity or compound heterozygosity for these mutations is rare. A second limitation is that we cannot rule out an association of epilepsy with the studied ACADS genotypes with an OR smaller than 2.4. However, given the results of our study the probability of an OR larger than 2.4 is only 2.5 % and therefore not very likely.
In conclusion, our study shows that the prevalence of SCADD in the Netherlands is at least 1 / 1 000 newborns. Because this is in contrast with the low number of patients diagnosed clinically, it contributes to the hypothesis that SCADD has no clinical relevance. Our study does not provide evidence for an association between SCADD based on the most common ACADS genotypes and epilepsy. This suggests that SCADD is not an important risk factor for the development of epilepsy and metabolic investigations aimed to diagnose SCADD for childhood epilepsy of unknown origin cannot be recommended.
